Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest metastatic prostate cancer Stories

2014-03-11 23:22:25

UVA study’s surprising finding: Direct treatment of tumor prolongs survival. Charlottesville, VA (PRWEB) March 11, 2014 Contrary to the standard approach to treating metastatic prostate cancer, direct treatment of the primary tumor appears to prolong survival significantly, a new study suggests. The surprising findings have prompted the researchers to launch clinical trials that could upend the accepted treatment of the disease. Prostate Cancer Survival Rate Prostate cancer is the most...

2014-02-03 08:27:25

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher(®) prostate cancer test to FEDMED Payors. FEDMED is a national provider network that covers over 40 million lives. The Decipher( )prostate cancer classifier directly measures a patient's biological risk of developing metastatic prostate cancer. GenomeDx, which discovered and developed the Decipher test, will provide laboratory services...

2014-01-30 08:31:31

Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2014 ASCO Genitourinary Symposium SAN DIEGO, Jan. 30, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced new data demonstrating that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting the probability of developing metastatic prostate cancer, outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy. In addition,...

2013-09-30 08:29:17

SAN DIEGO and VANCOUVER, British Columbia, Sept. 30, 2013 /PRNewswire/ -- GenomeDx Biosciences Inc, announced today it has closed a Series B financing round led by Merck Global Health Innovation Fund (GHIF) and other investors including Baird Capital Partners, aeris CAPITAL AG and CD Ventures. This additional capital will be used to further expand the commercialization of the Decipher(TM) prostate cancer test, the first and only commercially available genomic test that predicts the...

2013-07-30 23:03:40

The North Shore-LIJ Health System Department of Radiation Medicine is offering Radium-223 (Xofigo) treatment for men with metastatic prostate cancer that has spread to the bones. New Hyde Park, NY (PRWEB) July 30, 2013 The North Shore-LIJ Health System Department of Radiation Medicine is offering Radium-223 (Xofigo) treatment for men with metastatic prostate cancer that has spread to the bones. If prostate cancer grows outside of the prostate gland, it spreads into nearby tissues or...

2013-06-25 08:29:06

Decipher genomic test independently forecasts risk of metastatic disease better than PSA, Gleason Score, and other commonly used risk assessment tools as determined by clinical outcomes SAN DIEGO, June 25, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced the publication of data demonstrating its Decipher(TM) test outperformed existing risk assessment tools for predicting metastatic prostate cancer in patients following prostate surgery. Decipher more accurately...

2013-06-11 20:55:17

Study reveals new hybrid molecular imaging system is as good as PET/CT gold standard for restaging patients with metastatic prostate cancer When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to plan the best possible treatment. A relatively new imaging system that simultaneously combines positron emission tomography and...

2013-05-29 08:30:11

~New indication provides physicians with option to be used earlier in treatment of the disease, with hope of delaying chemotherapy~ TORONTO, May 29, 2013 /CNW/ - Janssen Inc. announced today that Health Canada has approved the once-daily, oral medication ZYTIGA(®) (abiraterone acetate), for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who are asymptomatic or mildly symptomatic after failure of androgen...

2013-04-29 08:27:42

Additional validation data of Decipher(TM) prostate cancer test to be presented at AUA 2013 SAN DIEGO, April 29, 2013 /PRNewswire/ -- GenomeDx Biosciences announced today that it has expanded an existing research agreement with the Mayo Clinic. The expanded agreement includes exclusive license to certain Mayo developed intellectual property along with exclusivity covering co-developed intellectual property. The agreement also includes continued access to the clinical data...

2013-04-04 12:16:56

Despite menopause-like side effects, continuous hormone treatment is superior to intermittent therapy A study published today in the New England Journal of Medicine recommends a dramatic shift in the way doctors treat metastatic prostate cancer. "These results have changed the way I treat patients," said Ian M. Thompson Jr., M.D., director of the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio and senior author on the international...